Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Sandoz Group Ltd ( (CH:SDZ) ) just unveiled an update.
Sandoz has secured European Commission marketing authorization for Ondibta, a biosimilar insulin glargine in a pre-filled pen developed with Gan & Lee Pharmaceuticals, for the treatment of diabetes mellitus in adults, adolescents and children from two years of age, matching the reference product Lantus SoloStar in safety, quality and efficacy. The product, expected to launch by early 2027, is positioned to intensify price competition in Europe’s fast‑growing diabetes market, potentially improving affordability and access for tens of millions of patients as regional diabetes prevalence and related healthcare expenditure continue to climb. The approval strengthens Sandoz’s strategic push into diabetes care, reinforces its long-standing leadership in biosimilars, and supports its broader plan to capture a substantial share of the projected USD 320 billion biosimilar market over the next 10 years through partnership-based commercialization and an expanding pipeline.
The most recent analyst rating on (CH:SDZ) stock is a Buy with a CHF70.00 price target. To see the full list of analyst forecasts on Sandoz Group Ltd stock, see the CH:SDZ Stock Forecast page.
More about Sandoz Group Ltd
Sandoz Group AG, headquartered in Basel, Switzerland, is a global leader in affordable medicines with a strong focus on generics and biosimilars. Employing more than 20,000 people of 100 nationalities, the company offers a portfolio of around 1,300 products that span conditions from common illnesses to cancer, and it pioneered the first biosimilar in 2006. In 2024, Sandoz generated USD 10.4 billion in net sales, and continues to expand its biosimilars portfolio—now 13 marketed products and 27 in development—as it targets a sizeable global biosimilar opportunity over the next decade.
Average Trading Volume: 721,993
Technical Sentiment Signal: Buy
Current Market Cap: CHF26.36B
Learn more about SDZ stock on TipRanks’ Stock Analysis page.